Skip to main content

Table 1 Effects of drotrecogin on mortality in National Registry data

From: Practical aspects of treatment with drotrecogin alfa (activated)

Registry/Trial

Country

Patients treated with DrotAA (% of cases)

ARR

OR (95% CI)

PROWESS

International

1,690

6.1%

0.8 (0.69 to 0.94)

 

UK [21]

1,245 (6.3%)

 

0.75 (0.68 to 0.83)

 

Poland [22]

302 (9.3%)

17.3%

 

PROGRESS

International [20]

882 (7%)

 

0.75 (0.63 to 0.9)

 

Belgium [24]

430

12.8%

0.61 (0.40 to 0.92)

  1. ARR, absolute risk reduction; CI, confidence interval; DrotAA, drotrecogin alfa (activated); OR, odds ratio; PROGRESS, Promoting Global Research Excellence in Severe Sepsis; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.
Back to article page

Critical Care

ISSN: 1364-8535